LLY: Lilly(Eli) & Co Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 483,335.18
Enterprise Value ($M) 499,679.68
Book Value ($M) 11,149.30
Book Value / Share 12.40
Price / Book 43.35
NCAV ($M) -22,333.10
NCAV / Share -24.83
Price / NCAV -21.64

Profitability (mra)
Return on Invested Capital (ROIC) 0.22
Return on Assets (ROA) 0.14
Return on Equity (ROE) 0.75

Liquidity (mrq)
Quick Ratio 0.87
Current Ratio 1.13

Balance Sheet (mrq) ($M)
Current Assets 21,331.60
Assets 54,814.00
Liabilities 43,664.70
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
02-10 13G/A Pnc Financial Services Group, Inc. 5.25 -0.11
02-09 13G/A Vanguard Group Inc 7.73 6.02
02-01 13G/A BlackRock Inc. 6.90 2.49
01-25 13G/A Lilly Endowment Inc 10.83 -4.20

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2023-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2023 COMMISSION FILE NUMBER 001-6351 ELI
2023-04-27 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2023 COMMISSION FILE NUMBER 001-6351 EL
2023-02-22 10-K Annual Report on Form 10-K
2022-11-01 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2022 COMMISSION FILE NUMBER 001-635

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2023-09-29 343,867 2,967,708 11.59
2023-09-28 295,244 2,178,763 13.55
2023-09-27 303,934 2,004,174 15.17
2023-09-26 273,796 1,864,471 14.68

(click for more detail)

Similar Companies
JATT.U – JATT Acquisition Corp Units, each consisting of one Class A ordinary share, and one-half of one rede JNJ – Johnson & Johnson
LCI – Lannett Co., Inc. MRK – Merck & Co Inc
MYOV – Myovant Sciences Ltd


Financial data and stock pages provided by
Fintel.io